Status: current, Sufficiently defined by necessary conditions definition status. Date: 31-Jul 2018. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3692758017 | Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
| 3692760015 | Benzocaine 20 mg/g and salicylamide 50 mg/g cutaneous gel | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| 46793101000001114 | Salicylamide 5% / Benzocaine 2% gel | en | Synonym | Active | Entire term case sensitive | SNOMED CT United Kingdom Edition module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Is a | Product containing benzocaine | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has active ingredient | Benzocaine | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Is a | Product containing benzocaine and salicylamide | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has manufactured dose form | Cutaneous AND/OR transdermal dosage form | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has active ingredient | Salicylamide | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has manufactured dose form | Gel | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has manufactured dose form | Conventional release cutaneous gel | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Is a | Product containing benzocaine in topical dosage form | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has concentration strength denominator value | 1 | false | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Count of base of active ingredient | 2 | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has concentration strength denominator value | 1 | false | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has concentration strength denominator unit | gram | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has concentration strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has concentration strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has concentration strength denominator unit | gram | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has precise active ingredient | Salicylamide | false | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has concentration strength numerator value | 20 | false | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has basis of strength substance | Salicylamide | false | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has basis of strength substance | Benzocaine | false | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has precise active ingredient | Benzocaine | false | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has concentration strength numerator value | 50 | false | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Is a | Product containing only benzocaine and salicylamide in cutaneous dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has basis of strength substance | Salicylamide | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has basis of strength substance | Benzocaine | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has precise active ingredient | Benzocaine | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has precise active ingredient | Salicylamide | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has manufactured dose form | Cutaneous dose form | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Count of base of active ingredient | 2 | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has manufactured dose form | Conventional release cutaneous gel | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has NHS dm+d (dictionary of medicines and devices) VMP (Virtual Medicinal Product) ontology form and route | gel.cutaneous ontology form and route | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has NHS dm+d (dictionary of medicines and devices) VMP (Virtual Medicinal Product) route of administration | Topical route | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has NHS dm+d (dictionary of medicines and devices) controlled drug category | Controlled drug category No Controlled Drug Status | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has NHS dm+d (dictionary of medicines and devices) dose form indicator | Continuous dose form indicator | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Is a | Salicylamide + Benzocaine | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has active ingredient | Benzocaine | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has NHS dm+d (dictionary of medicines and devices) VMP (Virtual Medicinal Product) route of administration | Cutaneous | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has active ingredient | Salicylamide | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has manufactured dose form | Gel | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has active ingredient | Salicylamide | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has manufactured dose form | Conventional release cutaneous gel | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Count of base of active ingredient | 2 | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Count of base of active ingredient | 2 | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Count of base of active ingredient | 2 | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has manufactured dose form | Conventional release cutaneous gel | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has manufactured dose form | Gel | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | VMP prescribing status (attribute) | VMP valid as a prescribable product | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | VMP non-availability indicator | Not available | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has manufactured dose form | Gel | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has specific active ingredient | Salicylamide | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has specific active ingredient | Benzocaine | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Has dispensed dose form | Gel | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Is a | Virtual medicinal product | true | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Intralgin gel | Is a | False | Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Inferred relationship | Existential restriction modifier | |
| Intralgin gel (3M Health Care Ltd, Pharmaceuticals Division) | Is a | True | Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Inferred relationship | Existential restriction modifier | |
| Salicylamide 5% / Benzocaine 2% gel 50 gram | Is pack of | False | Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Inferred relationship | Existential restriction modifier | |
| Salicylamide 5% / Benzocaine 2% gel 50 gram | Has VMP | True | Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | Inferred relationship | Existential restriction modifier |
This concept is not in any reference sets
FHIR